Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Has Average Target Price of $21.57

by · The Cerbat Gem

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) have earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $21.57.

Several brokerages have issued reports on VIR. Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a research note on Thursday, August 6th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Vir Biotechnology in a report on Monday. HC Wainwright reiterated a “buy” rating on shares of Vir Biotechnology in a research note on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a report on Wednesday, July 8th. Finally, Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th.

Check Out Our Latest Analysis on VIR

Vir Biotechnology Trading Down 1.1%

Vir Biotechnology stock opened at $11.17 on Wednesday. Vir Biotechnology has a twelve month low of $4.82 and a twelve month high of $11.94. The stock has a 50 day moving average of $10.19 and a two-hundred day moving average of $9.71. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of -6.01 and a beta of 1.59.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.14. The company had revenue of $238.95 million during the quarter, compared to analyst estimates of $135.88 million. During the same period in the previous year, the firm posted ($0.80) EPS. The company’s revenue for the quarter was up 19582.5% on a year-over-year basis. Equities analysts predict that Vir Biotechnology will post -1.84 earnings per share for the current year.

Hedge Funds Weigh In On Vir Biotechnology

A number of large investors have recently made changes to their positions in VIR. Squarepoint Ops LLC lifted its position in shares of Vir Biotechnology by 384.9% during the 2nd quarter. Squarepoint Ops LLC now owns 126,141 shares of the company’s stock valued at $1,285,000 after acquiring an additional 100,128 shares during the period. Arizona State Retirement System boosted its stake in shares of Vir Biotechnology by 29.9% during the 2nd quarter. Arizona State Retirement System now owns 32,255 shares of the company’s stock worth $329,000 after acquiring an additional 7,416 shares in the last quarter. Corient Private Wealth LP grew its holdings in shares of Vir Biotechnology by 5.9% in the 2nd quarter. Corient Private Wealth LP now owns 311,002 shares of the company’s stock worth $3,169,000 after acquiring an additional 17,314 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Vir Biotechnology by 25.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 164,147 shares of the company’s stock worth $1,673,000 after acquiring an additional 33,644 shares during the period. Finally, Empowered Funds LLC purchased a new position in Vir Biotechnology in the 2nd quarter valued at approximately $180,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

(Get Free Report)

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing treatments and preventive therapies for serious infectious diseases. The company uses immunologic insights, antibody technology, cellular approaches and other scientific platforms to address diseases in which the immune system plays a central role.

Vir’s research and development programs have included therapies for chronic hepatitis B, influenza, human immunodeficiency virus (HIV) and COVID-19. Its pipeline has included investigational antibody and immunomodulatory candidates such as tobevibart and elebsiran for hepatitis B, as well as programs designed to prevent or treat other viral infections.

Featured Stories